---
layout: default
title: Cetuximab
parent: Model Prediction Only (L5)
nav_order: 516
evidence_level: L5
indication_count: 10
---

# Cetuximab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Cetuximab: From EGFR-Targeted Cancer Therapy to Chondroid Hamartoma

## One-Sentence Summary

Cetuximab is an EGFR-blocking antibody. The provided data do not list its approved indication text.
The TxGNN model predicts it may be effective for **chondroid hamartoma**, but this prediction has **0 clinical trials** and **0 publications** behind it, so it is a model output only.

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Chondroid hamartoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 2 records (both are BLA125084, so effectively one license) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Cetuximab is known as an antibody that blocks EGFR (epidermal growth factor receptor), which is its main pharmacological rationale.

Chondroid hamartoma is a benign mesenchymal lesion with no established dependence on EGFR signaling. The provided data document no mechanistic link between EGFR blockade and this disease. The only support is the TxGNN score of 99.95% (rank 1834), which is not enough on its own to justify further investment.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| BLA125084 | ERBITUX | Solution | ImClone LLC |

The pack lists this BLA twice with identical details, and the approved indication text is not provided. Cetuximab is a biologic, so the authorization is a BLA rather than an NDA.

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Skin reactions and infusion reactions, which are reported in the Evidence Pack literature. For other parameters, refer to the package insert. |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found. The literature in the pack for other predicted indications describes infusion reactions and skin toxicity with cetuximab. These were not verified against the label.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no trials, no literature and no documented mechanism, so it is a model output only (L5). The core safety data (package insert warnings and contraindications) are also missing.

**To proceed, the following is needed:**
- FDA package insert warnings and contraindications (blocking data gap)
- Mechanism of action data from DrugBank
- A literature and trial search specific to chondroid hamartoma to check whether any real evidence exists
- Consideration of other predicted indications in the same pack, which have more evidence: cystic neoplasm (L3, one Phase 1/2 trial in adenoid cystic carcinoma and a Phase II salivary gland study) and pre-malignant neoplasm (L4, EGFR chemoprevention rationale in head and neck lesions)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

